India Pharma Outlook Team | Friday, 13 June 2025
.jpeg "Orion Partners with Shilpa Medicare for Albumin Supply Deal")
Shilpa Biocare, an integral Shilpa Medicare subsidiary, has signed a commercial supply contract across Europe with Orion Corporation for its recombinant human albumin, ahead of the Bio International Bio Convention in Boston.
Recombinant albumin, currently under development, is manufactured using a non-human expression system by offers important advantages such as free virus production, improved safety, and scalability. This technology addresses limitations of traditional man-derived albumin and is ready to serve a variety of therapeutic applications.
According to the agreement, Orion gains exclusive rights to the market, distributing and selling the product throughout Europe. Shilpa Biocare will receive marks based on development and regulatory progress.
Satu Ahomäki, Orion's executive vice president of Generics and Consumer Health, commented, "Our collaboration with Shilpa improves our Hospital Generic Portfolio. We are excited to bring this next-generation albumin to patients across Europe." This agreement occurs at a strategic moment, as Shilpa Biocare anticipates the greater involvement of Bio Boston Biotechnology companies.
The company has been expanding its CDMO services in beauty and oncology, supported by mammal and microbial manufacturing resources on a commercial scale.
Madhav Bhutada, managing director of Shilpa Biocare, said, “Our partnership with Orion marks a crucial milestone. Validates our experience in developing biological and supports our mission to provide high-quality recombinant collaboration.”
Also Read: Indian MedTech Champions Circular Economy with Biodegradable Medical Products
The partnership emphasizes Shilpa Biocare's ambitions to become a global participant in the biological space and CDMO, especially within the rapidly evolving landscape of recombinant protein therapies.
